Corporatism and Big Pharma
The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma's corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: April 1, 2016
More about this publication?
- Ethical Human Psychology and Psychiatry is no longer available to subscribers on Ingenta Connect. Please go to http://connect.springerpub.com/content/sgrehpp to access your online subscription to Ethical Human Psychology and Psychiatry.